AuroBlog - Aurous Healthcare Clinical Trials blog

NOVEMBER 1, 2022

As drug companies have embarked on an initiative to launch affordable medicines for rare diseases in India, experts have called for using pharmacogenetics to develop treatments and whole genome sequencing to identify etiologies.

Development 176

Development Genome Genomics Medicine 176

Pharmaceutical Technology

SEPTEMBER 1, 2022

Guardant Health has extended a partnership with Merck KGaA, Darmstadt, Germany, to aid in expediting precision oncology therapeutics development. Under the collaboration, the companies will use the GuardantINFORM real-world evidence (RWE) platform to boost works for developing Merck’s precision cancer pipeline.

Development 162

Development Genome Genomics Medicine 162

Drug Discovery World

DECEMBER 29, 2023

Known as ‘CReATiNG’ (Cloning Reprogramming and Assembling Tiled Natural Genomic DNA), the method offers a simpler and more cost-effective approach to constructing synthetic chromosomes. The thing about most synthetic genomics research is that it involves building chromosomes or genomes from scratch using chemically synthesised DNA pieces.

Genome 52

Genome Genomics DNA Scientist 52

pharmaphorum

JANUARY 26, 2023

2022 was a banner year for genomics. In March, the collaborative T2T consortium published the first complete telomere-to-telomere sequence of the human genome, filling in the last 8% of the 3 billion base pairs that make up our DNA.

Genome 116

Genome Genomics Genome Project Genetics 116

Scienmag

JULY 11, 2022

SAN DIEGO, Calif.

Genome 83

Genome Genomics Medicine Drugs 83

pharmaphorum

JUNE 13, 2022

Canary Wharf’s bid to become a new hub for the life sciences sector in the UK has been given a boost following the decision by Genomics England to relocate to the development. It was announced three years after the European Medicines Agency (EMA) relocated from the site to Amsterdam as a result of the UK’s exit from the EU.

Genome 106

Genome Genomics Life Science Genome Project 106

Pharmaceutical Technology

OCTOBER 11, 2022

Biotechnology company Ochre Bio has raised $30m in a Series A financing round to develop RNA therapies for chronic liver diseases. Ochre Bio will also expand its platforms for drug discovery and development that include a new RNA chemistry and an exploratory platform for expanding its research to more liver diseases.

RNA 130

RNA Development Genome Genomics 130

Pharmaceutical Technology

APRIL 12, 2023

Foundation Medicine has announced it will supply a tissue-based test as a companion diagnostic for Bristol Myers Squibb’s (BMS) recently acquired ROS1/TRK inhibitor repotrectinib. Repotrectinib has been developed to combat cancer resistance to existing therapies and exert consistent anti-tumor activity.

Genome 130

Genome Genomics In-Vitro Gene 130

Drug Discovery World

JUNE 21, 2023

The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), Exact Sciences, Guardant Health, Illumina, MSD and Novartis have come together to launch the European Coalition for Access to Comprehensive Genomic Profiling (ECGP).

Genome 52

Genome Genomics Medicine Clinical Trials 52

STAT News

OCTOBER 3, 2022

A Swedish scientist won the 2022 Nobel Prize in medicine or physiology on Monday for his groundbreaking research into the evolutionary history of humankind. Pääbo unlocked scientists’ understanding of how genes from these extinct relatives have been passed down to present-day humans.

Medicine 142

Medicine Contamination Research DNA 142

pharmaphorum

OCTOBER 31, 2022

Verge Genomics has joined a select group of biotechs who have taken a drug discovered and developed using artificial intelligence into human testing. Since then others have followed suit, including BenevolentAI with its BEN-2293 candidate for atopic dermatitis and Insilico Medicine with idiopathic pulmonary fibrosis therapy SM001-055.

Genome 128

Genome Genomics Drugs RNA 128

Drug Discovery World

APRIL 24, 2024

The strategic partnership will combine Variant Bio’s genomic discovery capabilities and VB-Inference platform with Evotec’s knowledge of antifibrotic drug discovery. They have the experience and track record in converting breakthrough science into medicines that matter for patients.”

Development 52

Development In-Vivo In-Vitro Genome 52

STAT News

JULY 29, 2022

Precision medicine — tailoring a treatment to an individual’s disease — requires understanding the individual’s biological characteristics. More than 80% of genomics studies have been conducted in people of European descent. Read the rest…

Medicine 111

Medicine DNA Genome Genomics 111

pharmaphorum

MARCH 24, 2022

GlaxoSmithKline has thrown its financial and drug development weight behind LifeMine Therapeutics, a US startup that aims to find new therapeutics from fungi – widely regarded as an underexplored resource of biologically-active compounds. The post GSK partners LifeMine on fungi-derived medicines appeared first on.

Medicine 91

Medicine Genome Genomics Engineer 91

pharmaphorum

OCTOBER 19, 2022

million ($40 million) first-round financing that will be used to explore so-called ‘dark’ regions of the human genome. M Ventures’ Dr Bauke Anninga said that that the startup has a “differentiated platform technology has the potential to fundamentally shift the way we discover and develop precision medicines.

Genome 57

Genome Genomics Gene Gene Expression 57

Drug Discovery World

JANUARY 11, 2024

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. The post New podcast: Revolutionary technology for drug discovery and development appeared first on Drug Discovery World (DDW).

Development 59

Development Drugs Genome Genomics 59

Drug Discovery World

OCTOBER 26, 2022

A study by the Qatar Genome Research Consortium, led by Dr Lotfi Chouchane from Weill Cornell Medicine-Qatar, has reported the first landscape of cancer germline mutations – hereditary mutations – in the Qatari population. . These variants increase the risk of developing breast cancer in women and prostate cancer in men. .

Genome 52

Genome Genomics Biobanking Genetics 52

Roots Analysis

FEBRUARY 27, 2024

The global genome editing market is anticipated to grow at a CAGR of 12.6% The global genome editing market is anticipated to grow at a CAGR of 12.6% The biopharmaceutical pipeline includes close to 500 gene therapies , several of which are being developed based on CRISPR technology. during the forecast period 2023-2035.

Genome 40

Genome Genomics Gene Gene Editing 40

Pharmaceutical Technology

NOVEMBER 8, 2022

Fulgent Genetics has acquired clinical-stage therapeutics development firm Fulgent Pharma for a total deal price of nearly $100m. With the takeover, Fulgent Genetics intends to transform into a completely integrated precision medicine firm focusing on oncology from a genomic diagnostic business.

Genetics 130

Genetics Development Genome Genomics 130

Medical Xpress

MARCH 27, 2023

To develop treatments that may one day entirely rid the body of HIV infection, scientists have long sought to identify all of the places that the virus can hide its genetic code.

Genome 75

Genome Genomics Scientist Genetics 75

Drug Discovery World

AUGUST 3, 2023

This is the latest episode of the free DDW narrated podcast, “What lies in the future for genomics and big data?”, and “ Why a recent advancement is a giant leap for human genomics ”. Listen here: The post New podcast on the future for genomics and big data appeared first on Drug Discovery World (DDW).

Big Data 52

Big Data Genome Genomics Pharma Companies 52

Pharmaceutical Technology

FEBRUARY 13, 2023

SOPHiA GENETICS is expanding its collaboration with AstraZeneca to include multimodal approaches for developing cancer drugs. The post SOPHiA GENETICS and AstraZeneca partner for oncology drugs development appeared first on Pharmaceutical Technology.

Genetics 130

Genetics Development Drugs Genome 130

Drug Discovery World

NOVEMBER 7, 2022

A new study led by Medical Research Council-funded researchers from UCL has found that tailoring the analysis of whole genome sequencing to individual patients could double the diagnostic rates of rare diseases. . Consequently, the UK has established itself at the forefront of diagnostic whole genome sequencing. Context .

Genome 52

Genome Genomics Genetics Genetic Disease 52

Roots Analysis

JANUARY 22, 2024

This resulted in the discovery of an individualized concept of treatment known as oncology precision medicine which primarily utilizes the patient’s genomic information to provide gene-targeted diagnostics and therapeutics. What is Oncology Precision Medicine?

Medicine 40

Medicine Genetics Genome Genomics 40

Drug Discovery World

FEBRUARY 12, 2024

Dr Pandora Pound , Fellow Oxford Centre for Animal Ethics explores the hinderances of animal testing in pharma and why new technologies such AI, genomics and synthetic biology c an further drug development. Why has there been so little progress in medicine? 1 Can this really be regarded as a success?

Medicine 59

Medicine Genome Genomics Drugs 59

Drug Discovery World

JANUARY 11, 2024

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. The post Revolutionary technology for drug discovery and development appeared first on Drug Discovery World (DDW).

Development 52

Development Drugs Genome Genomics 52

Drug Discovery Today

NOVEMBER 2, 2022

and Oxford, UK – November 2, 2022 – ROME Therapeutics and Enara Bio, two leading biotechnology companies focused on developing novel medicines driven by insights to the dark genome, today announced that they will host the inaugural Dark Genome Symposium on Monday, November 7, 2022 at ROME’s headquarters in Boston.

Genome 40

Genome Genomics Research Medicine 40

Drug Discovery World

APRIL 10, 2023

India is traditionally known as ‘the pharmacy of the world’ due to its huge pharmaceuticals manufacturing capacity and high quantity of exports, particularly generic medicines and vaccines. Industry has grown tremendously in the last five years with timely policy interventions, infrastructure development and thrust on education and training.

Genome 52

Genome Genomics Drugs Life Science 52

Pharmaceutical Technology

SEPTEMBER 22, 2022

You have just received the results from your whole genome sequencing test, offered through your public health provider, and discovered that you have a 75% chance of developing a rare form of cancer. If a vaccine is not yet available, and the cancer has begun to grow, personalised medicine will be your best therapeutic solution.

Genome 342

Genome Genomics Clinical Trials Clinical Trials 342

Drug Discovery World

APRIL 7, 2023

The Series A funding will be used to further advance Mosaic’s pipeline of targeted oncology therapies for biomarker-stratified populations, progressing its lead programmes through preclinical development to IND-enabling studies. Mosaic is the most recent spin-out company from the Wellcome Sanger Institute, a world leader in genome research.

Development 52

Development Genome Genomics Research 52

pharmaphorum

DECEMBER 21, 2021

In a recent webinar held by pharmaphorum, in partnership with IQVIA, a discussion was held looking at how to make academic and commercial medical research more efficient, while also looking at the opportunity of genomic data to bring benefits to patients and healthcare systems. The potential to leverage genomic data.

Development 91

Development Genome Genomics Drugs 91

FDA Law Blog

NOVEMBER 2, 2023

Lewis, Senior Regulatory Device & Biologics Expert — On October 20, 2023, FDA announced the availability of the final guidance authored by CBER titled “Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies.” It finalized a draft guidance published in 2022.

Medicine 59

Medicine Gene Therapy Gene Production 59

Scienmag

APRIL 30, 2021

Credit: University of New Mexico Jeremy Edwards, director of the Computational Genomics and Technology (CGaT) Laboratory at The University of New Mexico, and his colleagues at Centrillion Technologies in Palo Alto, Calif.

Development 96

Development Genome Genomics Research 96

Drug Discovery World

FEBRUARY 7, 2024

His academic lab is technology-driven and focuses on developing and applying proteomic technologies to the study of underlying disease mechanisms, as well as the identification of diagnostic and prognostic markers across several different disease areas. He also highlights the importance of keeping these factors, amongst others, in mind.

Medicine 59

Medicine Protein FDA Approval DNA 59

Scienmag

AUGUST 7, 2020

Credit: UTHSC Neil Hayes, MD, MS, MPH, division chief of Hematology and Oncology at the University of Tennessee Health Science Center, is among recipients of the 2020 Team Science Awards from the American Association for Cancer Research (AACR) for his contributions to developing The Cancer Genome Atlas (TCGA), a groundbreaking multisite project to (..)

Genome 86

Genome Genomics Research Development 86

Camargo

NOVEMBER 11, 2020

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. Still, navigating such patent issues during drug development can be difficult, and Camargo can assist in finding a safe course. Ken Phelps.

Development 242

Development Bioequivalency Generic Drugs Production 242

pharmaphorum

SEPTEMBER 16, 2022

With approximately one third of all current FDA-approved drugs targeting GPCRs, Verily/Sosei Heptares are looking to expedite GPCR research within not only immunology, but also gastroenterology and immuno-oncology as well, and the latest data bodes well for future development of therapeutic options in these areas. What, then, is the solution?

Development 125

Development Research Drugs Clinical Trials 125